NASDAQ:TLRY - Nasdaq - US88688T1007 - Common Stock - Currency: USD
Overall TLRY gets a fundamental rating of 2 out of 10. We evaluated TLRY against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of TLRY have multiple concerns. TLRY is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.79% | ||
ROE | -34.64% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 30.88% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.11 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.51 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.62 | ||
Quick Ratio | 1.61 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 31.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:TLRY (7/24/2025, 12:08:06 PM)
0.6965
-0.04 (-5.38%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.86 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.26 | ||
P/tB | 1.23 | ||
EV/EBITDA | 31.7 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.79% | ||
ROE | -34.64% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 30.88% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.11 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 12.7 | ||
Cap/Depr | 27.68% | ||
Cap/Sales | 4.39% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.62 | ||
Quick Ratio | 1.61 | ||
Altman-Z | -0.51 |